FDA Clears New Blood Test for Alzheimer’s Diagnosis
A new blood test, the Lumipulse, has been cleared by the FDA to help diagnose Alzheimer's disease in individuals 55 and older experiencing cognitive decline, offering a less invasive diagnostic tool compared to traditional methods like brain scans or spinal…
Lafayette, IN, November 9, 2026 — The U.S. Food and Drug Administration (FDA) has granted clearance for the Lumipulse blood test, a new tool intended to aid in the diagnosis of Alzheimer’s disease. This development is noted as a trending topic in Lafayette, Indiana.
The Lumipulse test is designed for individuals aged 55 and older who are experiencing cognitive decline. Its clearance by the FDA marks a step toward potentially more accessible diagnostic pathways for Alzheimer’s disease.
Traditionally, diagnosing Alzheimer’s disease has involved more invasive procedures. These have often included neuroimaging techniques such as positron emission tomography (PET) scans or magnetic resonance imaging (MRI), or the collection of cerebrospinal fluid (CSF) through a lumbar puncture, commonly known as a spinal tap. The Lumipulse blood test offers a less invasive alternative, aiming to simplify the diagnostic process for patients and healthcare providers.
Further details regarding the specific timeline of the Lumipulse test’s availability in Lafayette, IN, or the specific healthcare providers offering it were not immediately available. The summary provided does not include information on the companies involved in the test’s development or manufacturing, the exact date of the FDA clearance, or any specific outcomes from clinical trials beyond its intended use for diagnosis.
Story summarized from the original created by LeAnne Gendreau on www.wlfi.com, see more information here.
Media gallery
